RT Journal Article
T1 Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
A1 Suárez-García, Inés
A1 Moreno, Cristina
A1 Ruiz-Algueró, Marta
A1 Pérez-Elías, María Jesús
A1 Navarro, Marta
A1 Díez Martínez, Marcos
A1 Viciana, Pompeyo
A1 Pérez-Martínez, Laura
A1 Górgolas, Miguel
A1 Amador, Concha
A1 de Zárraga, Miguel Alberto
A1 Jarrín, Inma
A1 Cohort of the Spanish HIV/AIDS Research Network (CoRIS), 
K1 Cohort studies
K1 Darunavir
K1 HIV infection
K1 Highly active antiretroviral therapy
AB The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014-2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL)  We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL  EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.
YR 2020
FD 2020-07-20
LK http://hdl.handle.net/10668/15964
UL http://hdl.handle.net/10668/15964
LA en
DS RISalud
RD Apr 8, 2025